TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07321106: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorect

Sponsor: Cartography Biosciences · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT07321106 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07321106 Rescue Dossier →